FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, specifically oncology. Degarelix in an initial dose of 160 to 320 mg and then in a maintaining dose of 60 to 160 mg is administered into the individual once every 20-36 days for treating prostate cancer in the above individual.
EFFECT: given treatment provides a lower rate and/or probability of a side effect different from a side effect related to an injection point with the above side effect specified in a cardiovascular and/or vascular side effect, a musculoskeletal disturbance and/or a connective tissue disease, as well as urinary or renal disorders.
15 cl, 23 tbl, 6 dwg, 1 ex
